Technical analysis of Fennec Pharmaceuticals Inc. (FENC): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc.
Price Performance
| 1 month | -11.12% |
| 3 months | +16.45% |
| Year-to-date | +37.01% |
| 1 year | +21.68% |
| 3 years | +43.15% |
52-Week Range
| 52-week High | $13.25 |
| 52-week Low | $5.65 |
| Avg Volume (90d) | 270K |
Technical Indicators
| SMA 50 | $11.08 |
| SMA 200 | $8.75 |
| Beta | 0.93 |
| 30-day Volatility (annualised) | 69.4% |
| Price vs SMA 50 | -4.8% |
| Price vs SMA 200 | +20.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $8.20 | |
| 2025-11 | $8.19 | -0.1% |
| 2025-12 | $7.70 | -6.0% |
| 2026-01 | $7.59 | -1.4% |
| 2026-02 | $8.49 | +11.9% |
| 2026-03 | $6.15 | -27.6% |
| 2026-04 | $6.49 | +5.5% |
| 2026-05 | $9.93 | +53.0% |
| 2026-06 | $10.75 | +8.3% |
| 2026-07 | $9.57 | -11.0% |
| 2026-08 | $12.35 | +29.0% |
| 2026-09 | $10.55 | -14.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.05 | $88M |
| 2026-09-15 | | |
| 2026-09-15 | $0.14 | $2.28B |
| 2026-09-15 | | |
Price
| Price | $10.55 |
| Market Cap | $366M |
| Exchange | NASDAQ |
| Country | US |
Financial Health
| Piotroski F-Score | 1 |
| Altman Z-Score | 0.49 |